Shots:
- Ascidian has entered a global research & licensing agreement with Eli Lilly to discover & develop therapies for undisclosed monogenic kidney diseases, with an option to expand the collaboration to additional targets
- As per the deal, Lilly will obtain exclusive target-specific rights to Ascidian’s RNA exon editing tech for undisclosed targets, with Ascidian leading discovery & selected preclinical activities, while Lilly will oversee additional preclinical work, clinical development, manufacturing, & commercialization
- Under the terms, Ascidian will receive ~$1.9B, incl. an upfront, development & commercial milestone payments, & tiered royalties on global sales, while retaining rights to pursue other kidney targets independently or with partners
Ref: PRnewswire| Image: Ascidian and Eli Lilly | Press Release
Related News: Hanmi Pharm Inks ~$1.26B Deal with Eli Lilly to Advance Sonefpeglutide
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
